Last reviewed · How we verify

NCT07317297

Extracorporeal Shockwave Therapy in the Treatment of Peyronie's Disease

Recruiting now NA Last updated 16 January 2026
What this trial tests

NA trial testing Extracorporeal Shockwave Therapy in Peyronie Disease in 50 participants. Currently enrolling.

Timeline
10 January 2026
Primary endpoint
15 February 2026
30 March 2026

Quick facts

Lead sponsorUskudar University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment50
Start date10 January 2026
Primary completion15 February 2026
Estimated completion30 March 2026
Sites1 location across Azerbaijan

Drugs / interventions tested

Conditions studied

Sponsor

Uskudar University

Who can join

Adults 18 to 65, male only, with Peyronie Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation of the effectiveness of extracorporeal shock wave therapy in the treatment of Peyronie's disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Extracorporeal Shockwave Therapy

Trials testing the same drug.

Other recruiting trials for Peyronie Disease

Currently open trials in the same condition.

Other Uskudar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07317297.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing